New York, NEW YORK, November 4, 2014
Aquavit Pharmaceuticals welcomes Mary Lupo, MD, FAAD as its newest Scientific Advisory Board member. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened the Lupo Center for Aesthetic and General Dermatology where she has pioneered the concept of combined therapies such as resurfacing, filler injections, skin care protocols and neuromodulation. Since 2002, she has been a BOTOX® Cosmetic trainer and was on the original advisory board for Sculptra Aesthetic in 2003. Additionally, in 2004, she was chosen to be an FDA investigator for Juvéderm and participated in the FDA approval for BOTOX® for the treatment of crow’s feet. Dr. Lupo was the clinical investigator that launched Juvéderm in Australia in 2007.
Dr. Lupo graduated summa cum laude from Newcomb College of Tulane University in 1976 and completed her internship at Ochsner Foundation Hospital and dermatology residency at Tulane affiliated hospitals. For 30 years, she has acted as Tulane University’s Health Science Center. She added cosmetic injectable therapy, sclerotherapy and chemical peels to the core curriculum training for Tulane residents. She is a fellow of the AAD and ASDS for which she served as member of board of directors. Dr. Lupo is a past president of the Women’s Dermatological Society and past treasurer of the Louisiana Dermatological Society. Furthermore, she has been named a top doctor by Castle Connelly. Dr. Lupo is a frequent speaker at prestigious facial plastic surgery meetings in the United States such as AAD and ASDS as well as facial plastic surgery meetings abroad.
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies.